drugset / Trial / NCT07142278
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Phase 1
Not yet recruiting
24 enrolled
Nuravax, Inc.
Institute for Molecular Medicine · collabNational Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.
Timeline
- Start
- 2025-11-01
- Primary completion
- 2027-04-01
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DUVAX | Vaccine | 200 ug | Intramuscular |
| Subject | DUVAX | Vaccine | 400 ug | Intramuscular |